The Danish biotech company, Arcedi Biotech, announces the launch of Evita test completeTM, a technology that will revolutionize the choices available for pregnant women who want to get a clear genetic overview of their unborn child. The test looks for serious chromosomal aberrations – using nothing else than a blood sample. Gå til Dansk artikel …
“I have always had an appetite for impossible tasks”, said the late Professor Steen Kølvraa when interviewed for a Danish newspaper six years ago when he talked about the research team’s progress in their endeavors to identify and isolate fetal cells in maternal blood. Gå til Dansk artikel At the time, Steen Kølvraa had been …
The story behind a new test: When perseverance leads to great achievements Read More »
Tager EVITA testen fordi tryghed og vished er vigtigt Mikael Christensen og Katrine Nielsen fra Skanderborg venter deres barn nummer to. De har valgt, at Katrine får taget Evita testen for at få vished for, at deres kommende barn er, som det skal være. ”For os handler EVITA testen om tryghed og sikkerhed for, at …
Case stories (in Danish): Vores oplevelse med EVITA TEST Read More »
Purpose: Proof of concept of the use of cell-based non-invasive prenatal testing (cbNIPT) as an alternative to chorionic villus sampling (CVS) following preimplantation genetic testing for monogenic disorders (PGT-M). Method: PGT-M was performed by combined testing of short tandem repeat (STR) markers and direct mutation detection, followed by transfer of an unaffected embryo. Patients who …
Background: In gestational trophoblastic disease, the prognosis is related to the genetic constitution. In some cases, taking a biopsy is contraindicated. Methods: In a pregnant woman, ultrasound scanning suggested hydatidiform mole. To explore if the genetic constitution can be established without taking a biopsy (or terminating the pregnancy), cell-free DNA and circulating gestational trophoblasts were …
With guidelines for noninvasive prenatal testing expanding and payers reimbursing for these screenings, researchers search for new testing methods… Read more
Cell-based non-invasive prenatal testing (cbNIPT) based on circulating fetal extravillous trophoblasts (fEVTs) has shown to be possible in gestational week (GW) 10–13. Prenatal testing is relevant for a wider time period than GW10–13, but it is unclear if fEVTs are present in sufficient numbers for cbNIPT at other time points during pregnancy. We present the …
Main office
Tabletvej 1 | DK-7100 Vejle | Denmark
Aarhus office
INCUBA | Palle Juul-Jensens Boulevard 82 |
DK-8200 Aarhus N | Denmark
If you have any questions regarding ARCEDI,
you are welcome to contact us
CVR nr.: 25577922
ARCEDI’s prenatal tests can give you peace of mind concerning your future child. Learn more about EVITA TEST COMPLETE and EVITA TEST GENDER at evitatest.com
